545
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden

, , , , , , , , & show all
Pages 756-762 | Accepted 29 Mar 2013, Published online: 17 Apr 2013

References

  • Chard DT, Dalton CM, Swanton J, et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psych 2001;82:176-9
  • Langer-Gould A, Brara S, Beaber B, et al. (2012). the incidence of clinically isolated syndrome is higher in African Americans and whites compared with Hispanics and Asians. Neurology 2012;78:Meeting Abstracts 1
  • Ahlgren C, Odén A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011;17:901-8
  • Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006;7(2 Suppl):S75-S85
  • Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012;11:1, 33-41.
  • Dental and Pharmaceutical Benefits Agency. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Stockholm, Sweden: Dental and Pharmaceutical Benefits Agency. 2003. Available at: http://www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf. Accessed 14 March 2013
  • Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford, England: Oxford University Press, 2006
  • Tappenden P, Chilcott J, O’Hagan T, et al. (2001). Cost-effectiveness of beta-interferons and glatiramer acetate in the management of multiple sclerosis: final report to the National Institute for Clinical Excellence. Sheffield, UK: School of Health and Related Research (ScHARR), 2001.
  • World Health Organization/Multiple Sclerosis International Federation. Atlas: Multiple Sclerosis Resources in the World. Switzerland, Geneva: World Health Organization. 2008
  • Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:3-17
  • Comi G, Freedman MS, De Stefano N, et al. Effect of two dosing frequencies of subcutaneous interferon beta-1a on conversion to MS and MRI measures of disease in patients with a first clinical demyelinating event: 3-year results of Phase III, double-blind, multicentre trials (REFLEX/REFLEXION). Lyon, France: ECTRIMS, 2012.
  • Brex PA, Miszkiel KA, O'Riordan JI, et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2001;70:390-3
  • Kappos, L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97
  • GetData Graph Digitizer v2.24. 2012. http://getdata-graph-digitizer.com/. Accessed December 19, 2012.
  • Oanda. New York, United States: OANDA Corporation. 2012. http://www.oanda.com/currency/historical-rates/. Accessed December 19, 2012.
  • Statistics Sweden. Consumer Price Index. Stockholm, Sweden: Statistics Sweden. 2012. http://www.scb.se/Pages/TableAndChart____272152.aspx. Accessed February 28, 2013.
  • Dental and Pharmaceutical Benefits Agency. Drug Price Database. Stockholm, Sweden: Dental and Pharmaceutical Benefits Agency. 2012. http://www.tlv.se/beslut/sok/lakemedel/. Accessed December 19, 2012.
  • Statistics Sweden. Life tables 2006--2010. Stockholm, Sweden: Statistics Sweden. 2012. http://www.scb.se/Statistik/BE/BE0701/2001I10/Figur_3.xls. Accessed December 19, 2012.
  • Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4
  • Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18(Suppl):S68-80
  • Schwander B, Gradl B, Zöllner Y, et al. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe – The HEALTH Model. Value Health 2009;12:857-71
  • Sorenson C. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison. Commonwealth Fund Pub 2010;91:1-13
  • Polman CH, Reingold C, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
  • Iskedjian M, Walker JH, Gray T, et al. Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult Scler 2005;11:542-51
  • Lazzaro C, Bianchi C, Peracino L, et al. Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. Neurol Sci 2009;3:21-31
  • Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.